Some Fixed Point Theorems on Ordered Metric Spaces and Application

I. Altun,H. Simsek

DOI: https://doi.org/10.1155/2010/621469

2010-01-21

Abstract:We present some fixed point results for nondecreasing and weakly increasing operators in a partially ordered metric space using implicit relations. Also we give an existence theorem for common solution of two integral equations.

What problem does this paper attempt to address?

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy

Zhi-Hua Huang,Lei Shi,Jing-Wen Ma,Zhan-Yi Sun,Hui Cai,Yong-Xiang Chen,Yu-Fen Zhao,Yan-Mei Li

DOI: https://doi.org/10.1021/ja211725s

2012-05-30

Abstract:In the development of vaccines for epithelial tumors, the key targets are MUC1 proteins, which have a variable number of tandem repeats (VNTR) bearing tumor-associated carbohydrate antigens (TACAs), such as Tn and STn. A major obstacle in vaccine development is the low immunogenicity of the short MUC1 peptide. To overcome this obstacle, we designed, synthesized, and evaluated several totally synthetic self-adjuvanting vaccine candidates with self-assembly domains. These vaccine candidates aggregated into fibrils and displayed multivalent B-cell epitopes under mild conditions. Glycosylation of Tn antigen on the Thr residue of PDTRP sequence in MUC1 VNTR led to effective immune response. These vaccines elicited a high level antibody response without any adjuvant and induced antibodies that recognized human breast tumor cells. These vaccines appeared to act through a T-cell independent pathway and were associated with the activation of cytotoxic T cells. These fully synthetic, molecularly defined vaccine candidates had several features that hold promise for anticancer therapy.
Non‐natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity

Ana Guerreiro,Ismael Compañón,Foivos S. Lazaris,Carlos Labão-Almeida,Paula Oroz,Mattia Ghirardello,Marta C. Marques,Francisco Corzana,Gonçalo J. L. Bernardes

DOI: https://doi.org/10.1002/anie.202411009

2024-09-16

Angewandte Chemie International Edition

Abstract:Glycopeptides derived from the glycoprotein mucin-1 (MUC1) have shown potential as tumor-associated antigens for cancer vaccine development. However, their low immunogenicity and non-selective conjugation to carriers present significant challenges for the clinical efficacy of MUC1-based vaccines. Here, we introduce a novel vaccine candidate based on a structure-guided design of an artificial antigen derived from MUC1 glycopeptide. This engineered antigen contains two non-natural amino acids and has an α-S-glycosidic bond, where sulfur replaces the conventional oxygen atom linking the peptide backbone to the sugar N-acetylgalactosamine. The glycopeptide is then specifically conjugated to the immunogenic protein carrier CRM197 (Cross-Reactive Material 197), a protein approved for human use. Conjugation involves selective reduction and re-bridging of a disulfide in CRM197, allowing the attachment of a single copy of MUC1. This strategy results in a chemically defined vaccine while maintaining both the structural integrity and immunogenicity of the protein carrier. The vaccine elicits a robust Th1-like immune response in mice and generates antibodies capable of recognizing human cancer cells expressing tumor-associated MUC1. When tested in mouse models of colon adenocarcinoma and pancreatic cancer, the vaccine is effective both as a prophylactic and therapeutic use, significantly delaying tumor growth. In therapeutic applications, improved outcomes were....

chemistry, multidisciplinary
Fully Synthetic Self-Adjuvanting Thioether-Conjugated Glycopeptidelipopeptide Antitumor Vaccines For The Induction Of Complement-Dependent Cytotoxicity Against Tumor Cells

Hui Cai,Zhan-Yi Sun,Zhi-Hua Huang,Lei Shi,Yu-Fen Zhao,Horst Kunz,Yan-Mei Li

DOI: https://doi.org/10.1002/chem.201203709

2013-01-01

Chemistry - A European Journal

Abstract:Glycopeptides of tumor-associated mucin MUC1 are promising target structures for the development of antitumor vaccines. Because these endogenous structures were weakly immunogenic, they were coupled to immune-response-stimulating T-cell epitopes and the Pam3Cys lipopeptide to induce strong immune responses in mice. A new thioether-ligation method for the synthesis of two- and three-component vaccines that contain MUC1 glycopeptides as the B-cell epitopes, a T-cell epitope peptide, and the Pam3CSK4 lipopeptide is described. The resulting fully synthetic vaccines were used for the vaccination of mice, either in a liposome with Freunds adjuvant or in aqueous PBS buffer. The three-component vaccines that contained the Tetanus Toxoid P2 T-cell epitope peptide induced strong immune responses, even when administered just in PBS. By activation of the complement-dependent cytotoxicity (CDC) complex, the antisera induced the killing of tumor cells.
Ventilation is stimulated by small reductions in arterial pressure in the awake dog.

P. Ohtake,D. B. Jennings

DOI: https://doi.org/10.1152/JAPPL.1992.73.4.1549

1992-10-01

Journal of Applied Physiology

Abstract:Changes in arterial pressure commonly accompany respiratory adaptations. The purpose of this study was to determine, in awake dogs (n = 6), the degree to which small acute decreases in arterial pressure affect ventilation and acid-base balance. Mean arterial pressure (MAP) was reduced by 6 +/- 2, 10 +/- 3, and 16 +/- 2% by intravenous infusion of sodium nitroprusside for sequential 20-min periods. In another experiment, the ventilatory response to hypercapnia was determined during MAP reduction of 16 +/- 3%. Step reductions in MAP were accompanied by increases in minute ventilation (maximum increase 152 +/- 75%) and step reductions in arterial PCO2 (PaCO2; maximum reduction -4.8 +/- 0.8 Torr). Although eupneic PaCO2 threshold was lowered during MAP reduction, ventilatory sensitivity to CO2 remained unchanged. Despite the lowered PaCO2, arterial [H+] remained constant (acid-base balance was maintained) as a result of a concurrent decrease in strong ion difference. Plasma renin activity increased during MAP reduction (93 +/- 39%) and may have contributed to the increase in minute ventilation, inasmuch as angiotensin II can stimulate respiration by a central mechanism. Evidence is provided that nitroprusside is unlikely to be a primary factor in these hypotensive responses. We conclude that relatively modest decreases in MAP have a consistent stimulatory effect on respiratory control. Therefore it is important to take into account effects of small changes in MAP when interpreting mechanisms for respiratory responses in awake animals.
Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.

Hui Cai,Zhi-Hua Huang,Lei Shi,Yu-Fen Zhao,Horst Kunz,Yan-Mei Li

DOI: https://doi.org/10.1002/chem.201100217

2011-01-01

Chemistry - A European Journal

Abstract:The membrane-bound tumor-associated glycoprotein MUC1 is aberrantly glycosylated in cancer cells compared with normal cells, and is therefore considered an attractive target for cancer immunotherapy. However, tumor-associated glycopeptides from MUC1 do not elicit a sufficiently robust immune response. Therefore, antitumor vaccines were developed, which consist of MUC1 glycopeptides as the B epitopes and immune-stimulating toll-like receptor2 (TLR2) lipopeptide ligands. These fully synthetic vaccine candidates were prepared by solid-phase synthesis of the MUC1 glycopeptides. The Pam(3)Cys lipopeptide, also synthesized on solid-phase, was C-terminally coupled to oligovalent lysine cores, which N-terminally incorporate O-propargyl oligoethylene glycol acyl side chains. The MUC1 glycopeptides and lipopeptide lysine constructs were then conjugated by click chemistry to give oligovalent synthetic vaccines. Oligovalent glycopeptide-lipopeptide conjugates are considered more immunogenic than their monovalent analogues.
The appearance of acute phase protein after induced fever in man.

P. Hedlund,A. Frisk,H. Bucht

DOI: https://doi.org/10.1111/J.0954-6820.1948.TB04533.X

2009-04-24

Acta Medica Scandinavica

Abstract:
Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.

Pu-Guang Chen,Hong-Guo Hu,Zhan-Yi Sun,Qian-Qian Li,Bo-Dou Zhang,Jun-Jun Wu,Wen-Hao Li,Yu-Fen Zhao,Yong-Xiang Chen,Yan-Mei Li

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00720

2019-01-01

Molecular Pharmaceutics

Abstract:Constructing an effective therapeutic cancer vaccine is very attractive and promising for cancer immunotherapy. However, the poor immunogenicity of tumor antigens and suppression of the immune system in the tumor microenvironment are two major obstacles for developing effective cancer vaccines. Invariant NKT cells (iNKT cells), which are essential bridges between the innate and adaptive immune systems, can be rapidly activated by their agonists and, consequently, evoke whole immune systems. Herein, we conjugated a potent agonist of the iNKT cell, α-galactosylceramide (α-GalCer), with the tumor-associated MUC1 glycopeptide antigens as novel self-adjuvanting cancer vaccines through click chemistry. Immunological studies revealed that the mouse immune system was potently evoked and that high levels of tumor-specific IgG antibodies were elicited by vaccine conjugates without an external adjuvant. The produced antibodies could specifically recognize and bind to antigen-expressing cancer cells and, subsequently, induce cytotoxicity through complement-dependent cytotoxicity. Thus, the insertion of α-GalCer significantly improved the immunogenicity of the MUC1 glycopeptide and induced strong antigen-specific antitumor responses, indicating that α-GalCer is an effective built-in adjuvant for constructing potent chemical synthetic antitumor vaccines.
Amniotic-fluid lecithin and neonatal respiratory distress.

C. Fozzard,R. White

DOI: https://doi.org/10.1016/S0140-6736(72)90899-9

IF: 202.731

1972-02-19

The Lancet

Abstract:
[Diagnosis and epidemiology of Neospora caninum-associated abortions in cattle].

F. Conraths,G. Schares

1999-05-01

Abstract:Neospora caninum, a recently discovered protozoan parasite closely related to Toxoplasma gondii, has world-wide been recognized as an important cause of bovine abortion. N. caninum possesses a wide host range. The dog can be a definitive host for N. caninum. In cattle, the infection is transmitted transplacentally with high efficiency, while the majority of congenitally infected calves is clinically normal at birth and thereafter. Whether horizontal transmission occurs in cattle and whether this potential mode of transmission has epidemiological significance, remains to be elucidated. N. caninum-associated abortions can occur in epidemic or endemic form in a herd. The clinical symptoms of bovine neosporosis are confined to the occurrence of abortion, stillbirth and weak calves. Multifocal nonsuppurative encephalitis represents the most frequent pathohistological finding in N. caninum-associated abortions. The causative agent can be demonstrated by immunohistochemistry or polymerase chain reaction. Serological techniques can be used for indirect diagnosis. On the basis of the available diagnostic methods and the present knowledge about the epidemiology of the infection proposals are made regarding diagnosis, epidemiological assessment and prophylaxis of N. caninum-associated abortion problems in cattle herds.
The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response

Natascha Stergiou,Moritz Urschbach,Adele Gabba,Edgar Schmitt,Horst Kunz,Pol Besenius

DOI: https://doi.org/10.1002/tcr.202100182

Abstract:Tumor-associated carbohydrate antigens are overexpressed as altered-self in most common epithelial cancers. Their glycosylation patterns differ from those of healthy cells, functioning as an ID for cancer cells. Scientists have been developing anti-cancer vaccines based on mucin glycopeptides, yet the interplay of delivery system, adjuvant and tumor associated MUC epitopes in the induced immune response is not well understood. The current state of the art suggests that the identity, abundancy and location of the glycans on the MUC backbone are all key parameters in the cellular and humoral response. This review shares lessons learned by us in over two decades of research in glycopeptide vaccines. By bridging synthetic chemistry and immunology, we discuss efforts in designing synthetic MUC1/4/16 vaccines and focus on the role of glycosylation patterns. We provide a brief introduction into the mechanisms of the immune system and aim to promote the development of cancer subunit vaccines.
Glycopeptide Nanoconjugates Based on Multilayer Self-Assembly As an Antitumor Vaccine.

Yan-Fang Liu,Zhan-Yi Sun,Pu-Guang Chen,Zhi-Hua Huang,Yue Gao,Lei Shi,Yu-Fen Zhao,Yong-Xiang Chen,Yan-Mei Li

DOI: https://doi.org/10.1021/acs.bioconjchem.5b00150

IF: 4.7

2015-01-01

Bioconjugate Chemistry

Abstract:Antitumor vaccine, which is promising for tumor therapy, has been extensively studied. Some encouraging results of chemically synthetic vaccine designs based on the tumor-associated antigen mucin 1 have been achieved. However, some shortcomings such as low efficiency and difficult purification restrict their clinical application. To overcome these difficulties, we designed a novel antitumor vaccine of glycopeptide nanoconjugates based on the multilayer self-assembly through the interaction of positive and negative charges. This vaccine formed the spherical structure and effectively activated the macrophage in vitro. Besides, it also induced high titer of antibodies against mucin 1 glycopeptide. The induced antibodies could highly bind to the tumor cells and effectively kill them by activation of the complement dependent cytotoxicity complex. This novel strategy provides a new way for the development of simple and effective antitumor vaccine.
Injection Molding and its application to drug delivery.

L. Zema,G. Loreti,A. Melocchi,A. Maroni,A. Gazzaniga

DOI: https://doi.org/10.1016/j.jconrel.2012.01.001

IF: 11.467

2012-05-10

Journal of Controlled Release

Abstract:
Self-Adjuvanting Synthetic Antitumor Vaccines from Muc1 Glycopeptides Conjugated to T-Cell Epitopes from Tetanus Toxoid

Hui Cai,Mei-Sha Chen,Zhan-Yi Sun,Yu-Fen Zhao,Horst Kunz,Yan-Mei Li

DOI: https://doi.org/10.1002/anie.201300390

2013-01-01

Angewandte Chemie

Abstract:The T-helper epitope peptide P30 (green in the scheme) from tetanus toxoid was used as the immunostimulant in MUC1 glycopeptide antitumor vaccines and apparently also acts as a built-in adjuvant. P30-conjugated glycopeptide vaccines containing three glycans in the immunodominant motifs PDTRP and GSTAP induced much stronger immune responses and complement dependent cytotoxicity mediated killing of tumor cells when applied in plain PBS solution without complete Freund's adjuvant.
Isostructural bisdithiazolyl and bisthiaselenazolyl radicals: trends in bandwidth and conductivity.

Jaclyn L. Brusso,S. Derakhshan,M. Itkis,H. Kleinke,R. Haddon,R. T. Oakley,R. Reed,J. Richardson,C. Robertson,L. Thompson

DOI: https://doi.org/10.1021/IC061687C

IF: 4.6

2006-12-06

Inorganic Chemistry

Abstract:Reaction of N-alkylated pyridine-bridged bisdithiazolylium cations [1]+ (R1 =Me, Et; R2 =Ph) with selenium dioxide in acetic acid provides a one-step high-yield synthetic route to bisthiaselenazolylium cations [2]+ (R1 = Me, Et; R2 = Ph). The corresponding radicals 1 and 2 can be prepared by chemical or electrochemical reduction of the cations. Structural analysis of the radicals has been achieved by a combination of single-crystal and powder X-ray diffraction methods. While the two sulfur radicals 1 adopt different space groups (P3(1)21 for R1 = Me and P(-)1 for R1 = Et), the two selenium radicals 2 (space groups P3(1)21 for R1 = Me and P3(2)21 for R1 =Et) are isostructural with each other and also with 1 (R1 = Me, R2 = Ph). Variable-temperature magnetic measurements on all four compounds confirm that they are undimerized S = 1/2 systems, with varying degrees of weak intermolecular antiferromagnetic coupling. Variable-temperature electrical conductivity measurements on the two selenium radicals provide conductivities sigma(300 K) = 7.4 x 10-6 (R1 = Et) and 3.3 x 10-5 S cm-1 (R1 = Me), with activation energies, E(act), of 0.32 (R1 = Et) and 0.29 eV (R1 = Me). The differences in conductivity within the isostructural series is interpreted in terms of their relative solid-state bandwidths, as estimated from Extended Hückel band-structure calculations.
Synthesis and Immunological Evaluation of MUC1 Glycopeptide Conjugates Bearing N-acetyl Modified STn Derivatives As Anticancer Vaccines.

An Xiao,Xiu-Jing Zheng,Chengcheng Song,Yue Gui,Chang-Xin Huo,Xin-Shan Ye

DOI: https://doi.org/10.1039/c6ob01092j

2016-01-01

Organic & Biomolecular Chemistry

Abstract:Glycoprotein MUC1 is an attractive target for anti-tumor vaccine development. However, the weak immunogenicity of MUC1 remains a significant problem. To solve this problem, several STn derivatives with N-acetyl modifications were synthesized and incorporated into a 20-amino acid MUC1 tandem repeat sequence. The modified STn-MUC1 glycopeptides were further connected to a carrier protein keyhole limpet hemocyanin (KLH). The immunological effects of these synthetic vaccine conjugates were evaluated using the BALB/c mouse model. The results showed that vaccine V2 elicited higher titers of antibodies which cross-reacted with the native STn-MUC1 antigen. Moreover, the elicited antisera reacted with the STn-MUC1 antigen-positive tumor cells, indicating that the carbohydrate antigen modification strategy may hold potential to overcome the weak immunogenicity of natural MUC1 glycopeptides.
Development of novel self‐assembled vaccines based on tumour‐specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8+ T cells and enhancing their function

Wei Shi,Zhenzhen Tong,Shuang Chen,Qianqian Qiu,Jiaqi Zhou,Hai Qian

DOI: https://doi.org/10.1111/imm.13643

2023-03-24

Immunology

Abstract:self‐assembled vaccines for breast cancer immunotherapy Twelve conjugates with self‐assembly properties were designed and synthesized using MAGE‐A1 peptide and TLR2 agonist. Conjugate 6 (N‐Ac PamCS‐M‐6) had a more significant ability to promote dendritic cell maturation, CD8+ T cell activation, and subsequent killing of tumour cells. Vaccines based on tumour‐specific antigens are a promising approach for immunotherapy. However, the clinical efficacy of tumour‐specific antigens is still challenging. Twelve conjugates with self‐assembly properties were designed and synthesized using MAGE‐A1 peptide and TLR2 agonist, combined with different covalent bonds. All the developed conjugates formed spherical nanoparticles with a diameter of approximately 150 nm, and enhanced the efficacy of the peptide vaccines with the better targeting of lymph nodes. All the conjugates could well bind to serum albumin and improve the plasma stability of the individual antigenic peptides. In particular, conjugate 6 (N‐Ac PamCS‐M‐6) had a more significant ability to promote dendritic cell maturation, CD8+ T cell activation, and subsequent killing of tumour cells, with an in vivo tumour inhibition rate of 70 ± 2.9%. The interaction between specific response and the different conjugation modes was further explored, thereby providing a fundamental basis for novel immune anti‐tumour molecular platforms.

immunology
Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine

Shi-Hao Zhou,Yu-Ting Li,Ru-Yan Zhang,Yan-Ling Liu,Zi-Wei You,Miao-Miao Bian,Yu Wen,Jian Wang,Jing-Jing Du,Jun Guo

DOI: https://doi.org/10.3389/fimmu.2022.857779

IF: 7.3

2022-03-16

Frontiers in Immunology

Abstract:The tumor-associated antigen mucin 1 (MUC1) is an attractive target of antitumor vaccine, but its weak immunogenicity is a big challenge for the development of vaccine. In order to enhance immune responses against MUC1, herein, we conjugated small molecular toll-like receptor 7 agonist (TLR7a) to carrier protein BSA via MUC1 glycopeptide to form a three-component conjugate (BSA-MUC1-TLR7a). Furthermore, we combined the three-component conjugate with Alum adjuvant to explore their synergistic effects. The immunological studies indicated that Alum adjuvant and built-in TLR7a synergistically enhanced anti-MUC1 antibody responses and showed Th1-biased immune responses. Meanwhile, antibodies elicited by the vaccine candidate effectively recognized tumor cells and induced complement-dependent cytotoxicity. In addition, Alum adjuvant and built-in TLR7a synergistically enhanced MUC1 glycopeptide-specific memory CD8+ T-cell immune responses. More importantly, the vaccine with the binary adjuvant can significantly inhibit tumor growth and prolong the survival time of mice in the tumor challenge experiment. This novel vaccine construct provides an effective strategy to develop antitumor vaccines.

immunology
Synthesis and immunological evaluation of Mincle ligands-based antitumor vaccines

Kun Wang,Tong Zhang,Mingyang Liu,Danyang Wang,Haomiao Zhu,Zhaoyu Wang,Fan Yu,Yonghui Liu,Wei Zhao

DOI: https://doi.org/10.1016/j.cclet.2022.108065

IF: 9.1

2023-05-01

Chinese Chemical Letters

Abstract:The development of novel adjuvants constitutes a new strategy for the research of tumor vaccines. Immunomodulatory molecule adjuvants are one of the novel adjuvants that can effectively stimulate the pattern recognition receptors to activate the downstream pathways of immune cells. However, there are few studies on immunomodulatory molecular adjuvants associated with C-type lectin. It has been reported that GlcC 14 C 18 is a Mincle ligand with a relatively simple structure and strong adjuvant activity in vivo . Herein, we coupled GlcC 14 C 18 with MUC1 glycopeptide and evaluated its immune effect. In addition, we also synthesized α -GlcC 14 C 18 -MUC1 and β -GlcC 14 C 18 -MUC1 based on the two configurations of GlcC 1 4C 18 and compared their immune effects. The results show that both of the two configurations of the vaccine have a good immune effect, but to a certain extent, the immune effect of β -GlcC 14 C 18 -MUC1 is better than that of α -GlcC 14 C 18 -MUC1.

chemistry, multidisciplinary
Development of a minimal saponin vaccine adjuvant based on QS-21

Alberto Fernández-Tejada,Eric K. Chea,Constantine George,NagaVaraKishore Pillarsetty,Jeffrey R. Gardner,Philip O. Livingston,Govind Ragupathi,Jason S. Lewis,Derek S. Tan,David Y. Gin

DOI: https://doi.org/10.1038/nchem.1963

IF: 24.274

2014-06-01

Nature Chemistry

Abstract:Adjuvants are materials added to vaccines to enhance the immunological response to an antigen. QS-21 is a natural product adjuvant under investigation in numerous vaccine clinical trials, but its use is constrained by scarcity, toxicity, instability and an enigmatic molecular mechanism of action. Herein we describe the development of a minimal QS-21 analogue that decouples adjuvant activity from toxicity and provides a powerful platform for mechanistic investigations. We found that the entire branched trisaccharide domain of QS-21 is dispensable for adjuvant activity and that the C4-aldehyde substituent, previously proposed to bind covalently to an unknown cellular target, is also not required. Biodistribution studies revealed that active adjuvants were retained preferentially at the injection site and the nearest draining lymph nodes compared with the attenuated variants. Overall, these studies have yielded critical insights into saponin structure–function relationships, provided practical synthetic access to non-toxic adjuvants, and established a platform for detailed mechanistic studies.

chemistry, multidisciplinary
Multi-component self-assembled anti-tumor nano-vaccines based on MUC1 glycopeptides.

Z Y Sun,P G Chen,Y F Liu,B D Zhang,J J Wu,Y X Chen,Y F Zhao,Y M Li

DOI: https://doi.org/10.1039/c6cc02000c

IF: 4.9

2016-01-01

Chemical Communications

Abstract:Novel multi-component self-assembled nano-vaccines containing both Pam(3)CSK(4) and CpG were developed for the first time. These multi-component vaccines could effectively activate the macrophages in vitro and elicit strong antibody immune responses and anti-tumor immune responses in vivo.

Some Fixed Point Theorems on Ordered Metric Spaces and Application

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy

Non‐natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity

Fully Synthetic Self-Adjuvanting Thioether-Conjugated Glycopeptidelipopeptide Antitumor Vaccines For The Induction Of Complement-Dependent Cytotoxicity Against Tumor Cells

Ventilation is stimulated by small reductions in arterial pressure in the awake dog.

Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.

The appearance of acute phase protein after induced fever in man.

Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.

Amniotic-fluid lecithin and neonatal respiratory distress.

[Diagnosis and epidemiology of Neospora caninum-associated abortions in cattle].

The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response

Glycopeptide Nanoconjugates Based on Multilayer Self-Assembly As an Antitumor Vaccine.

Injection Molding and its application to drug delivery.

Self-Adjuvanting Synthetic Antitumor Vaccines from Muc1 Glycopeptides Conjugated to T-Cell Epitopes from Tetanus Toxoid

Isostructural bisdithiazolyl and bisthiaselenazolyl radicals: trends in bandwidth and conductivity.

Synthesis and Immunological Evaluation of MUC1 Glycopeptide Conjugates Bearing N-acetyl Modified STn Derivatives As Anticancer Vaccines.

Development of novel self‐assembled vaccines based on tumour‐specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8+ T cells and enhancing their function

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine

Synthesis and immunological evaluation of Mincle ligands-based antitumor vaccines

Development of a minimal saponin vaccine adjuvant based on QS-21

Multi-component self-assembled anti-tumor nano-vaccines based on MUC1 glycopeptides.